R&D na Sorrento yana mai da hankali kan haɓaka sabbin abubuwa a cikin COVID-19, maganin cutar kansa, cikakken kula da ciwo da cututtukan autoimmune.

Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
Shirye-shiryen COVID-19
COVISTIX (diagnostic) Gwajin Antigen gaggawa 0%* Izinin Amfani da Gaggawa (EUA) a Mexico (COFEPRIS), Brazil (ANVISA), da CE Alama a Turai COVIMARK™ (diagnostic) Gwajin Antigen gaggawa 0%* Aikace-aikacen da aka ƙaddamar a cikin Amurka da Kanada don Izinin Amfani da Gaggawa (EUA) VIREX (diagnostic) A Home Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 COVISHIELD™ (maganin magani) Neutralizing Antibody (IV) a cikin marasa lafiya da marasa lafiya 20%* FUJOVEE (Abivertinib) Mummunan COVID-19 a cikin Marasa lafiya na ICU 82%* Muhimmin Gwajin da ke jiran Cirewar FDA OQORY™ (COVI-MSC) ARDS saboda COVID-19 a cikin marasa lafiya na ICU 82%* Muhimmin gwaji a Brazil Mpro Mai hanawa (kwayoyin baka) Anti rigakafi 40%* Omicron mRNA rigakafin maganin 20%*
Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
immunotherapy
FUJOVEE (Abivertinib) Bayanin NSCLC 82%* FUJOVEE (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE (Abivertinib) prostate 20%* FUJOVEE (Abivertinib) Lupus 20%* FUJOVEE (Abivertinib) MS 20%* FUJOVEE (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *A cikin haɗin gwiwa tare da Lee's Pharm a China PD-L1 (STI-3031)** Cercical Cancer 82%* ** A Amurka kuma tare da haɗin gwiwar ImmuneOncia a Koriya CD47 Tumburai masu ƙarfi 40%* CD38 DAR-T Multiye Myeloma 40%* Saukewa: CD38D Amyloidosis, Multiple Myeloma, T-ALL, da esophageal 40%* Seprehvec™ oncolytic cutar Ciwon Ciwon Ciki; Ciwon daji na CNS 40%* Farashin BCMA Tuwon Ruwa 20%* Bevacizumab-ADNAB™ Ciwon daji na Endometrial 40%* A haɗin gwiwa tare da Mayo Clinic Bevacizumab-ADNAB™ Ovarian Ciwon daji 40%* A haɗin gwiwa tare da Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* A haɗin gwiwa tare da Mayo Clinic Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
Pain
ZTlido® 1.8% Neuralgia Postherpetic - PHN 99.8%* Gloperba® Maganin Gout (Na baka) 99.8%* SEMEXA (SP-102) Lumbar Radicular / Sciatica Pain 82%* SP-103 (Tsarin Topical Lidocaine 5.4%) Ciwon Baya 60.2%* SP-104 (An jinkirta fashe Low Dose Naltrexone) Fibromyalgia 20%* RTX (resiferatoxin) Epidural allura Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Kankara 60.3%* Sunan marayu RTX (resiferatoxin) Hanyar intra-articular Matsakaici zuwa Ƙunƙarar Ƙifin OA 60.2%*
Mabuɗin Shirye-shirye	Bayyanawa	Preclinical	Hakan na I	Phase II	Mataki na III/Pivotal	FDA Approval
Isar da Magungunan Lymphatic
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* A haɗin gwiwa tare da Mayo Clinic

Shirye-shiryen COVID-19
Mabuɗin Shirye-shirye (Alamar)	Phase
COVISTIX (diagnostic) FDA EU COVIMARK™ (diagnostic) FDA EU VIREX (diagnostic) PH III COVISHIELD™ (maganin magani) PH I FUJOVEE (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Inhibitor (kwayoyin baka) Ph II Omicron mRNA rigakafin Preclinical

immunotherapy
Mabuɗin Shirye-shirye (Alamar)	Phase
FUJOVEE (Abivertinib) Ph III FUJOVEE (Abivertinib) Ph II FUJOVEE (Abivertinib) Preclinical FUJOVEE (Abivertinib) Preclinical FUJOVEE (Abivertinib) Preclinical FUJOVEE (Abivertinib) Preclinical PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Tsarin Tumor) Ph I CD38 DAR-T (Multiple Myeloma) Ph I Saukewa: CD38D (Amyloidosis, Multiple Myeloma, T-ALL, da esophageal) Ph I Seprehvec™ oncolytic cutar (Tsarin Ciwon Ciwon Ciki; Ciwon Ciwon Ciki) PH I Farashin BCMA (Magungunan Liquid) Preclinical Bevacizumab-ADNAB™ (Cancer Endometrial) Ph I Bevacizumab-ADNAB™ (Cancer Ovarian) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Mabuɗin Shirye-shirye (Alamar)	Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval Gloperba® 1.8% Maganin Gout (Na baka) FDA Approval SEMEXA (SP-102) Ph III SP-103 (Tsarin Topical Lidocaine 5.4%) Ph II SP-104 (An jinkirta fashe Low Dose Naltrexone) Preclinical RTX (resiferatoxin) Epidural allura Ph II RTX (resiferatoxin) Hanyar intra-articular Ph II

Bayarwa Lymphatic
Mabuɗin Shirye-shirye (Alamar)	Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I